Kenvue Inc
Company Profile
Business description
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Contact
199 Grandview Road
SkillmanNJ08558
USAT: +1 908 874-1200
Sector
Consumer Defensive
Stock type
Defensive
Industry
Household & Personal Products
Fiscal Year End
31 December 2024
Employees
22,000
Kenvue Inc News & Analysis
stocks
9 best US dividend aristocrats to buy now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,474.30 | 4.40 | 0.05% |
| CAC 40 | 7,499.03 | 78.56 | -1.04% |
| DAX 40 | 19,011.65 | 153.10 | -0.80% |
| Dow JONES (US) | 42,007.32 | 189.20 | -0.45% |
| FTSE 100 | 8,280.89 | 9.97 | -0.12% |
| HKSE | 22,113.51 | 330.22 | -1.47% |
| NASDAQ | 17,875.99 | 49.13 | -0.27% |
| Nikkei 225 | 38,552.06 | 743.30 | 1.97% |
| NZX 50 Index | 12,572.66 | 120.97 | 0.97% |
| S&P 500 | 5,694.14 | 15.40 | -0.27% |
| S&P/ASX 200 | 8,205.20 | 7.00 | 0.09% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |